logo
Wyślij wiadomość
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
produkty
produkty
Do domu > produkty > API aktywny składnik farmaceutyczny > CAS 2212020-52-3,Orforg+lipron GLP-1RA Off-white to Light Yellow Powder with Molecular Formula C48H48F2N10O5 for T2DM and Obesity Management

CAS 2212020-52-3,Orforg+lipron GLP-1RA Off-white to Light Yellow Powder with Molecular Formula C48H48F2N10O5 for T2DM and Obesity Management

Szczegóły produktu

Miejsce pochodzenia: Chiny

Nazwa handlowa: Sunshine

Orzecznictwo: ISO

Numer modelu: 2212020-52-3

Warunki płatności i wysyłki

Minimalne zamówienie: Negocjacja

Cena: Zbywalny

Szczegóły pakowania: Torba foliowa aluminiowa, bęben

Czas dostawy: 7-15 dni roboczych

Zasady płatności: L/C, D/A, T/T, Western Union, D/P.

Możliwość Supply: 500 kg

Najlepszą cenę
Podkreślić:
CAS nr::
2212020-52-3
Wygląd::
Off-biały do ​​jasnożółtego proszku
Wzór molekularny::
C48H48F2N10O5
Waga cząsteczkowa::
882,97
Einecs nr::
960-735-6
Mdl no.::
Nie dotyczy
CAS nr::
2212020-52-3
Wygląd::
Off-biały do ​​jasnożółtego proszku
Wzór molekularny::
C48H48F2N10O5
Waga cząsteczkowa::
882,97
Einecs nr::
960-735-6
Mdl no.::
Nie dotyczy
CAS 2212020-52-3,Orforg+lipron GLP-1RA Off-white to Light Yellow Powder with Molecular Formula C48H48F2N10O5 for T2DM and Obesity Management
CAS 2212020-52-3
3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one
Product Description
Product Name: 3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one CAS 2212020-52-3
Synonyms
Orforg+lipron
Chemical & Physical Properties
Property Specification
Appearance Off-white to light yellow powder
Assay NLT 99%
Density 1.50 g/cm³
Solubility DMSO: 125 mg/mL (141.57 mM)
Application
Orforg+lipron is a non-peptide oral glucagon-like peptide-1 receptor agonist (GLP-1RA) widely used in the management of type 2 diabetes mellitus (T2DM) and obesity.
Available Intermediates
  • Bromo-2,6-dimethylfluorobenzene CAS 99725-44-7
  • 3-Aminobutanenitrile hcl CAS 1073666-54-2
  • 1,3-diethyl 2-(4-bromophenyl)-4-hydroxy-4-methyl-6-oxocyclohexane-1,3-dicarboxylate CAS 4759-57-3
  • (S)-ethyl-5-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-1H-indole-2-carboxylate CAS 2212021-77-5
  • (S)-1-(4-fluoro-1-methyl-1H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1H-imidazol-2(3H)-one hcl CAS 2212022-57-4
  • (R)-4-methyl-1,3,2-dioxathiolane 2,2-dioxide CAS 1006381-03-8
  • 4-Bromo-3-fluoro-2-methylaniline CAS 127408-03-1
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.